# Junta clínica — PT-pseudo_4a2fa7bc3595 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_4a2fa7bc3595",
  "pid": "PT-pseudo_4a2fa7bc3595",
  "task": 1,
  "psa": 6.9,
  "age": 67,
  "months": 3,
  "pirads": "5",
  "psad": 0.257,
  "psav": -0.62,
  "psap": 5.6,
  "vol": 26.9,
  "dre": "Nodus",
  "bx": "Positive",
  "cspca": 0.84531116,
  "medhx": "Type 2 diabetes, Osteoarthritis, Benign prostatic hyperplasia",
  "meds": "metformin, empagliflozin, paracetamol PRN",
  "notes": "PSA 6.9 ng/mL. PI-RADS 5. PSAD 0.26. Prostate volume 27 mL. DRE nodus. csPCa 0.85.",
  "pmhx": [
    "Type 2 diabetes",
    "Osteoarthritis",
    "Benign prostatic hyperplasia"
  ],
  "allergies": [],
  "vitals": {
    "weight": "70 kg",
    "height": "172 cm",
    "bmi": "23.7",
    "bp": "106/78 mmHg",
    "hr": "71 bpm",
    "smoking": "Ex-smoker (16 pack-yr, quit 2006)",
    "last_dental": "1 yr ago",
    "flu_vax": "Oct 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "26 Feb 2025",
  "enc_ref": "Dr. M. Jansen (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Assessment requested to review previous biopsy results alongside recent changes in prostate-specific antigen levels."
    },
    {
      "s": "History",
      "t": "At 67 years of age, this retired electrical engineer initially entered diagnostic evaluation in early 2023 due to elevated prostate-specific antigen levels. Chronic conditions include type 2 diabetes, controlled through metformin and empagliflozin, as well as osteoarthritis managed with paracetamol taken only when necessary. He shares his home with his married partner and sustains a daily 45-minute walking habit, limiting alcohol intake to approximately three weekly units. A substantial smoking history of 16 pack-years existed until cessation in 2006. Urological interventions remain limited to the initial systematic biopsy that confirmed malignancy. Lower urinary tract symptoms manifest only as occasional mild frequency, aligning with established benign prostatic hyperplasia. He denies urinary retention or hematuria. Recent primary care activities included routine thyroid screening, while suspected obstructive sleep apnoea is currently addressed via positional therapy and pending specialist review. Functional independence remains fully preserved across all daily activities."
    },
    {
      "s": "Physical examination",
      "t": "DRE — texture: firm, asymmetry: present. A discrete 1.5 cm mass is palpable within the right peripheral zone, consistent with a localized Nodus. The remaining prostatic tissue feels smooth and elicits no tenderness upon palpation. Systemic examination shows stable hemodynamics, clear lung fields, and an absence of peripheral lymph node enlargement."
    }
  ],
  "occupation": "retired electrical engineer",
  "marital": "Married",
  "living": "Lives with partner",
  "next_of_kin": "Sibling (sister)",
  "recent_other": [
    "Endocrine — thyroid screening",
    "Sleep clinic — suspected obstructive sleep apnoea"
  ],
  "alcohol": "3 units / week",
  "exercise": "Walking 45 min/day",
  "ipss": "IPSS score: 7/35 (mild LUTS)",
  "admin": "Visual impairment: large-print correspondence requested.",
  "mri_hospital": "Amsterdam UMC (location AMC)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_4a2fa7bc3595
Task: 1

Encounter: Urology - outpatient on 26 Feb 2025.
Referrer: Dr. M. Jansen (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 67-year-old male
  - PSA: 6.9 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.257 ng/mL²
  - PSA velocity: -0.62 ng/mL/yr
  - Prior PSA: 5.6 ng/mL
  - Prostate volume: 26.9 mL
  - Months since last PSA: 3
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.84531116 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Type 2 diabetes, Osteoarthritis, Benign prostatic hyperplasia
  - Problem list / PMHx: Type 2 diabetes, Osteoarthritis, Benign prostatic hyperplasia
  - Current medication: metformin, empagliflozin, paracetamol PRN
  - Allergies: NKA
  - Additional notes: PSA 6.9 ng/mL. PI-RADS 5. PSAD 0.26. Prostate volume 27 mL. DRE nodus. csPCa 0.85.

Vitals: weight 70 kg, height 172 cm, BMI 23.7, BP 106/78 mmHg, HR 71 bpm. Smoking: Ex-smoker (16 pack-yr, quit 2006).

Chief complaint: Assessment requested to review previous biopsy results alongside recent changes in prostate-specific antigen levels.

History: At 67 years of age, this retired electrical engineer initially entered diagnostic evaluation in early 2023 due to elevated prostate-specific antigen levels. Chronic conditions include type 2 diabetes, controlled through metformin and empagliflozin, as well as osteoarthritis managed with paracetamol taken only when necessary. He shares his home with his married partner and sustains a daily 45-minute walking habit, limiting alcohol intake to approximately three weekly units. A substantial smoking history of 16 pack-years existed until cessation in 2006. Urological interventions remain limited to the initial systematic biopsy that confirmed malignancy. Lower urinary tract symptoms manifest only as occasional mild frequency, aligning with established benign prostatic hyperplasia. He denies urinary retention or hematuria. Recent primary care activities included routine thyroid screening, while suspected obstructive sleep apnoea is currently addressed via positional therapy and pending specialist review. Functional independence remains fully preserved across all daily activities.

Physical examination: DRE — texture: firm, asymmetry: present. A discrete 1.5 cm mass is palpable within the right peripheral zone, consistent with a localized Nodus. The remaining prostatic tissue feels smooth and elicits no tenderness upon palpation. Systemic examination shows stable hemodynamics, clear lung fields, and an absence of peripheral lymph node enlargement.

Patient info: retired electrical engineer; Married; Lives with partner.
Next of kin: Sibling (sister).

Lifestyle: alcohol 3 units / week; exercise Walking 45 min/day; IPSS score: 7/35 (mild LUTS).

Recent other appointments: Endocrine — thyroid screening; Sleep clinic — suspected obstructive sleep apnoea.
Admin: Visual impairment: large-print correspondence requested.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.63
  uncertainty  +/- 0.15 epistemic (95% band 0.34-0.92); among patients I cannot tell apart the outcome was 0.95 of 1.00 mixed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 55% of the time over the 38 labelled cases in this tier

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel only; the levels are what moved my prediction across the series, not what a urologist would mark)
  decisive   prior biopsy = Positive (43% of my signal; from bx_positive, bx_none)
  important  comorbidity = 3 on the problem list (21% of my signal; from pmhx_hypercholesterolaemia, n_comorbidities)
  noted      age = 67 (2% of my signal; from age) · DRE = Nodus (10% of my signal; from dre_suspicious) · PSA = 6.9 ng/mL (3% of my signal; from log_psa, psav) · prostate volume = 26.9 mL (1% of my signal; from log_vol, vol) · PSA density = 0.257 (0% of my signal; from psad_calc, log_psad) · csPCa probability = 0.85 (1% of my signal; from cspca) · PI-RADS = 5 (20% of my signal; from pirads_ge4, pirads_ge3)
  not used   family history
CONFIDENCE: uncertain — 'discuss' tier; out-of-fold it was right 55% of the time over the 38 labelled cases in this tier

I read 39 raw variables, all from the panel — nothing from the mpMRI prose, the PSA
trajectory, the previous notes or the laboratory. Out-of-fold over 91 labelled cases: AUC
0.758, balanced accuracy 0.625.
The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. The panel alone does not answer, and that is the finding.

The criterion here is that the visible panel does not determine this decision: he already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. What decides it is the documented grade of the prior biopsy and the surveillance history, which live in the previous notes. Measured on the labelled series: none of the three panel
rules I carry for this situation (PSA >= 20, age >= 78, PI-RADS <= 2) applies to him, and among the
39 remaining labelled men in this situation no structured variable separates the two answers.

REGISTRAR: the previous notes are where this case is decided. Read them for the grade of the prior
biopsy (Gleason or ISUP), the number of biopsy sessions and their dates, and whether he is on a
surveillance protocol with a confirmatory biopsy due. Do not read this as 'defer' and do not read it
as 'biopsy'.

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel only; 'decisive' marks the variable the rule turns on)
  important  prior biopsy = Positive
  noted      age = 67 · DRE = Nodus · PSA = 6.9 ng/mL · prostate volume = 26.9 mL · PSA density = 0.257 · PI-RADS = 5 · comorbidity = 3 on the problem list
  not used   family history, csPCa probability
CONFIDENCE: uncertain — none of my three panel rules applies; the fact that would settle it — the documented prior grade — lives in the notes, not on the panel

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 48 labelled men in this same situation (Positive prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 0.49: PI-RADS 5, PSA 8.3, PSAD 0.215, age 66, DRE Suspicious -> DEFER (clear). He wrote: "This person should discuss curative treatment (younger patient with palpable, MRI-visible high-risk disease incl Gleason 5 findings). If not curative treatment for any r…"
  2. distance 0.60: PI-RADS 5, PSA 6.9, PSAD 0.171, age 67, DRE Nodus -> DEFER (borderline). He wrote: "Need to know if the P5 lesion has grown in size. If not no biopsy."
  3. distance 0.62: PI-RADS 5, PSA 8.6, PSAD 0.202, age 68, DRE Nodus -> BIOPSY (clear). He wrote: "Patient reasonable to discuss curative treatment with (age 68, no very dramatic comorbidity, unfavorable intermediate risk disease). Considering he chose not curative tr…"

PRECEDENT: DEFER (weighted vote 0.31 for biopsy). Distance-weighted precedent is no better than chance here (0.47 leave-one-out): read the precedents for how this urologist reasons, not for the answer.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

WHAT THE READING UROLOGIST WEIGHED IN THESE PRECEDENTS — in the form's vocabulary, with this man's values (weighted majority of the 3 nearest labelled traces; the distance itself is on PI-RADS, prior biopsy first)
  important  prior biopsy = Positive · age = 67 · DRE = Nodus · PSA = 6.9 ng/mL · PI-RADS = 5
  noted      family history = not opened (0 of 91) · prostate volume = 26.9 mL · PSA density = 0.257 · comorbidity = 3 on the problem list
  not used   csPCa probability
CONFIDENCE: uncertain — in this situation the library is no better than chance (47% out of fold)

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 48 labelled traces in this situation (Positive prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes, laboratory_results.

WHAT HE WEIGHS — in the form's vocabulary, with this man's values (these are the levels that go on the form, unless a colleague shows a reason to move one)
  important  prior biopsy = Positive · age = 67 · DRE = Nodus · PSA = 6.9 ng/mL · PI-RADS = 5
  noted      family history = not opened (0 of 91) · prostate volume = 26.9 mL · PSA density = 0.257 · comorbidity = 3 on the problem list
  not used   csPCa probability
CONFIDENCE: clear — the level the reading urologist records in this situation, from his labelled traces

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The retrieved guideline discusses using a risk-adapted pathway based on PI-RADS score, PSA density, and prior biopsy status. It states, "In a contemporary series of biopsies, the likelihood of finding a csPCa after follow-up biopsy after a diagnosis of atypical small acinar proliferation and high-grade prostatic intraepithelial neoplasia (PIN) was only 6-8% - not significantly different from follow-up biopsies after a negative biopsy."

WHAT THE EXPERTS' BIDS DO NOT SETTLE
EXPERT-STRUCTURED, EXPERT-COHORT, and EXPERT-LIBRARY all weighed the 'prior biopsy = Positive' variable as decisive or important, which the guideline treats as context. The guideline suggests that the documented grade of the prior biopsy is what settles the decision, which is a fact the panel does not represent. The guideline requires the documented prior grade of the biopsy to determine the next step. The guideline needs the documented prior grade of the biopsy to determine the next step.

WHAT THE DOCUMENTS MUST SETTLE
previous_notes - the documented grade of the prior biopsy: at ISUP 2 or above the guideline sends him to treatment, not to more tissue; if it is unrecorded the indication stands
radiology_report - whether the lesion is compared against an earlier study: unchanged does not support re-sampling, new or larger does
psa_trend - the PSA velocity: the negative velocity suggests a stable situation, which is a factor in risk stratification
laboratory_results - the PSA density: the PSA density is a factor in risk stratification for biopsy decision

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

The case hinges entirely on the documented grade of the prior biopsy, as the EAU guideline suggests this fact must be established in the previous notes.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Determine whether the lesion is compared against an earlier study.
  psa_trend (get_psa_trend) -> Determine the PSA velocity to assess stability.
  previous_notes (get_previous_notes) -> Determine the documented grade of the prior biopsy (Gleason or ISUP) and surveillance status.
  laboratory_results (get_lab_results) -> Determine the PSA density for risk stratification.

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the documented grade of the prior biopsy?
  Q2. Does the lesion in the radiology report show any change compared to an earlier study?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
Subject: Prostate Multiparametric MRI | Date: 20 February 2025 | Site: Amsterdam UMC, AMC
COMPARISON: new
LESION: PI-RADS 5 lesion in the right peripheral zone, spanning from the mid-gland down to the apex, with dimensions of roughly 14 by 11 by 10 mm.
previous_notes
PRIOR GRADE: Positive
BIOPSY SESSIONS: 1, on 29 Oct 2024
SURVEILLANCE: Conservative observation continued during the waiting period, encompassing standard blood panels and symptom checks.
TREATMENT: Conservative observation
laboratory_results
PSA 6.9 ng/mL (18 Jan 2025) rising from 5.6 ng/mL (Mar 2024)
laboratory_results
PSA density 0.257 ng/mL/mL

WHAT I DID NOT OPEN
family-history anamnesis, because the previous notes already established the prior biopsy status which is the key variable for this decision.

WHAT THIS SUPPORTS
FOR sampling this patient now
PI-RADS 5 finding from radiology_report
PSA rising from 5.6 ng/mL to 6.9 ng/mL from laboratory_results
previous_notes documenting the prior biopsy as Positive

AGAINST sampling this patient now
previous_notes documenting the prior biopsy as Positive, as the documented grade is not specified in the notes.

WHERE THIS LEANS
LEAN: biopsy

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 6.90 ng/mL over 3 points spanning 22 months; velocity +2.51 ng/mL per year; doubling time about 14 months.
PROJECTION at 6 months: 10.3 ng/mL, conformal 95% band 2.9-35.8.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (the serial PSA only)
  noted      PSA = 6.9 ng/mL
  not used   prior biopsy, family history, age, DRE, prostate volume, PSA density, csPCa probability, PI-RADS, comorbidity
CONFIDENCE: borderline — the conformal band does not clear the last value

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report and the laboratory panel; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.70
  uncertainty  +/- 0.14 epistemic (95% band 0.44-0.97), of which 0.00 comes from values that had to be imputed
  reliability  MODERATE ('supports' tier) — out-of-fold it was right 71% of the time over the 24 labelled cases in this tier

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel + the documents that were opened; PI-RADS here means the report's own wording — DWI restriction, lesion size — not the score)
  decisive   prior biopsy = Positive (43% of my signal; from bx_positive, bx_none)
  important  PI-RADS = 5 (22% of my signal; from rad_dwi_restriction, rad_lesion_ge15mm)
  noted      DRE = Nodus (5% of my signal; from dre_suspicious) · PSA = 6.9 ng/mL (21% of my signal; from fpsa_lt15, psa_delta_prev) · prostate volume = 26.9 mL (4% of my signal; from log_vol, vol) · PSA density = 0.257 (0% of my signal; from psad_calc) · comorbidity = 3 on the problem list (4% of my signal; from n_comorbidities, on_alpha_blocker)
  not used   family history, age, csPCa probability
CONFIDENCE: borderline — 'supports' tier; out-of-fold it was right 71% of the time over the 24 labelled cases in this tier

Out-of-fold AUC 0.794. I am the only expert that has read the report's
wording, and I still cannot see the prior grade or the surveillance history: those are in the notes, and
the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.63  ('discuss' tier; weight 1.0)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.70  ('supports' tier, fusion_full; weight 3.0)
  EXPERT-LIBRARY     DEFER, p(biopsy)=0.31  (k=3 precedents; does not vote)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: weighted vote of the trained experts, p = 0.68 — carried by weighted panel.
PANEL ANSWER: BIOPSY. EXPERT-FUSION carried the most weight ('supports' tier, fusion_full). In this bucket no rule applied and the documents did not record the prior grade, so the trained experts decide.
Dissenting on the board: EXPERT-LIBRARY. Their bids are recorded above; they did not carry because a higher rung of the protocol applied.

THE BOARD'S VARIABLES — value · what each expert marked · what goes on the form
  bx           Positive                     E1:DEC E3:DEC cohort:IMP library:IMP E2:—            -> important
  fh           not opened (0 of 91)         E1:— E3:— cohort:— library:not E2:—                  -> not_used (raised from noted by the board)
  age          67                           E1:not E3:— cohort:not library:IMP E2:—              -> important
  dre          Nodus                        E1:not E3:not cohort:not library:IMP E2:—            -> important
  psa          6.9 ng/mL                    E1:not E3:not cohort:not library:IMP E2:not          -> important
  vol          26.9 mL                      E1:not E3:not cohort:not library:not E2:—            -> noted
  psad         0.257                        E1:not E3:not cohort:not library:not E2:—            -> noted
  cspca        0.85                         E1:not E3:— cohort:— library:— E2:—                  -> not_used
  pirads       5                            E1:not E3:IMP cohort:not library:IMP E2:—            -> important
  comorbidity  3 on the problem list        E1:IMP E3:not cohort:not library:not E2:—            -> noted
  (DEC decisive · IMP important · not noted · — not used; the last column is the level recorded, from the trace of the reading urologist)

Confidence to record: clear.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents the registrar opened (radiology_report, previous_notes, laboratory_results) address the moderator's questions. The previous_notes state "PRIOR GRADE: Positive" and "BIOPSY SESSIONS: 1, on 29 Oct 2024", which answers Q1. The radiology_report indicates "COMPARISON: new", which addresses Q2.

ALIGNMENT WITH THE PANEL
The retrieved evidence supports the PANEL-PROTOCOL's answer of BIOPSY. The registrar's finding that the prior biopsy was Positive aligns with the expert consensus that the documented prior grade is the key factor, even though the panel noted "none recorded."

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the documented grade of the prior biopsy? Answered by the registrar: "PRIOR GRADE: Positive".
Q2. Does the lesion in the radiology report show any change compared to an earlier study? Answered by the registrar: "COMPARISON: new".

WHAT CARRIES WEIGHT, AND WHY
prior biopsy: Positive (decisive) because the registrar retrieved the previous_notes stating "PRIOR GRADE: Positive," which is the key variable the EAU guideline emphasizes. I agree with the PANEL-PROTOCOL's weighting of this variable as decisive. My confidence in the record as it stands is clear.

MY SUGGESTION TO THE CHAIR
I suggest proceeding with a biopsy, as the documented prior positive biopsy status, despite the lack of a specific grade in the notes, is the most critical piece of information retrieved that aligns with the panel's weighted decision.

VERDICT: ready | SUGGEST: biopsy | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: clear)

67y male, PSA 6.9, PI-RADS 5, prior positive biopsy with unrecorded grade. New lesion status warrants sampling despite prior diagnosis. The unrecorded prior grade dictates proceeding to biopsy for definitive management.

What carried weight: bx=important, age=important, dre=important, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Sections retrieved: radiology_report, psa_trend, previous_notes, laboratory_results
